|
Catalog Number UNK STRATTICE |
Device Problem
Adverse Event Without Identified Device or Use Problem (2993)
|
Patient Problems
Cellulitis (1768); Fistula (1862); Seroma (2069)
|
Event Type
Injury
|
Manufacturer Narrative
|
Conclusion: based on limited information, including no identification of the relevant lot number, a relationship between the event and strattice could not be determined.
Due to lack of information, strattice as a contributing factor cannot be ruled out.
The device remains implanted.
Lifecell reports the event in an abundance of caution.
Multiple attempts to obtain additional information are being made, including identification of the lot number.
Should additional information be reported, a follow up adverse event report will be submitted; otherwise this investigation is concluded.
|
|
Event Description
|
It was reported that a female patient underwent a reduction mammoplasty and was excessively reduced.
(date of surgery was not provided).
In a follow up procedure, the patient underwent a breast implant procedure to increase volume.
She also had three or four breast augmentation revisions including an initial revision in the summer of 2017 using strattice bilaterally to reinforce lateral capsulorrhaphy.
The patient did well but received a steroid injection in her back sometime in (b)(6) 2017.
(no indication was provided).
Subsequently, the patient started thinning at her lateral breast soft tissue.
In (b)(6) 2018, the patient developed cellulitis and seroma which responded to clindamycin.
A breast implant migrated cephalad and then returned to normal position.
In (b)(6) 2018, the patient developed recurrent seroma, cellulitis, and had spontaneous drainage of the seroma.
She now has a small fistula tract.
|
|
Search Alerts/Recalls
|
|
|